证券代码：002317 公告编号：2026-003 广东众生药业股份有限公司 关于使用闲置募集资金进行现金管理及 闲置自有资金进行委托理财的进展公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 一、概述 广东众生药业股份有限公司（以下简称"公司"）于 2025 年 9 月 18 日召开 了第八届董事会第二十七次会议及第八届监事会第二十七次会议，审议通过了 《关于使用部分闲置募集资金进行现金管理的议案》，同意公司在确保不影响募 集资金投资计划正常进行的情况下，使用不超过人民币 18,000.00 万元的闲置募 集资金进行现金管理，适时购买结构性存款、大额存单等安全性高的保本型产品。 现金管理期限为本次董事会审议通过之日起十二个月内。在上述额度和期限内资 金可滚动使用，但在任一时点的实际投资金额不超过人民币 18,000.00 万元，本 次使用部分闲置募集资金进行现金管理事项将在上述额度内，授权董事长具体实 施相关事宜。 公司于 2025 年 10 月 30 日召开了第八届董事会第二十八次会议和第八届监 事会第二十八次会议，审议通过了《关于使用闲置自有资金进行 ...

Group 1 - The Chinese medicine sector saw a rise of 0.54% on January 20, with *ST Changyao leading the gains [1] - The Shanghai Composite Index closed at 4113.65, down 0.01%, while the Shenzhen Component Index closed at 14155.63, down 0.97% [1] - Notable gainers in the Chinese medicine sector included *ST Changyao with a closing price of 0.53, up 20.45%, and ST Xiangxue with a closing price of 9.72, up 7.05% [1] Group 2 - The Chinese medicine sector experienced a net outflow of 23.25 million yuan from major funds, while retail investors saw a net inflow of 20.95 million yuan [2] - The top stocks by net inflow from retail investors included *ST Changyao and ST Xiangxue, with retail inflows of 2.20 million yuan and 4.16 million yuan respectively [3] - Major funds showed a significant net outflow in stocks like Zhongsheng Pharmaceutical and Yiling Pharmaceutical, with net outflows of 10.68 million yuan and 5.57 million yuan respectively [3]

Group 1 - The NMN concept index rose by 1.95%, ranking fourth among concept sectors, with 16 stocks increasing in value, including Meibang Technology which hit a 30% limit up [1] - Notable gainers in the NMN sector included Hongyang Sun, Youa Shares, and Chenguang Biology, which rose by 6.54%, 3.52%, and 3.35% respectively [1] - The sector experienced a net outflow of 51 million yuan in main funds, with six stocks seeing net inflows, led by Zhongsheng Pharmaceutical with a net inflow of 93.86 million yuan [2][3] Group 2 - The main fund inflow ratios were highest for Guoyao Modern, Zhongsheng Pharmaceutical, and Hongyang Sun, with net inflow rates of 6.13%, 4.99%, and 3.77% respectively [3] - The NMN concept fund inflow rankings showed Zhongsheng Pharmaceutical at 1.80% increase with a turnover rate of 11.13%, while Hongyang Sun had a 6.54% increase with a turnover rate of 9.10% [3][4] - Stocks like Yaba Chemical and Anqi Yeast showed negative fund flow, indicating potential concerns in their performance, with Yaba Chemical at -317.96 million yuan and Anqi Yeast at -610.36 million yuan [4]

国投证券研报指出，众生药业与齐鲁制药达成合作协议，共同推进GLP-1/GIP双靶药物RAY1225在中国 地区的商业化。GLP-1/GIP双靶药物RAY1225国内市场授权齐鲁制药，海外市场未来授权值得期待。齐 鲁制药国内商业化能力较强，RAY1225有望凭借其强大的商业化能力销售放量。未来RAY1225在国内 获批上市后有望凭借齐鲁制药强大的商业化能力实现销售放量。考虑到公司创新转型即将进入兑现阶 段，给予公司2026年PE60倍估值水平，对应12个月目标价为26.68元/股，维持"买入-A"的投资评级。 ...

证券日报网讯1月20日，众生药业（002317）在互动平台回答投资者提问时表示，公司RAY1225注射液 是具有全球自主知识产权的创新结构多肽药物，具有GLP-1受体和GIP受体双重激动活性，得益于优异 的药代动力学特性，具备每两周注射一次的超长效药物潜力，临床上拟用于2型糖尿病及肥胖/超重等患 者的治疗，目前正在积极推进III期临床试验。另外，RAY1225注射液获批开展新增适应症治疗"代谢相 关脂肪性肝炎"的药物临床试验。 ...

（文章来源：每日经济新闻） 每经AI快讯，有投资者在投资者互动平台提问：公司目前正在进行IND的RAY1225注射液是用于什么适 应症? 众生药业（002317.SZ）1月20日在投资者互动平台表示，公司RAY1225注射液是具有全球自主知识产权 的创新结构多肽药物，具有GLP-1受体和GIP受体双重激动活性，得益于优异的药代动力学特性，具备 每两周注射一次的超长效药物潜力，临床上拟用于2型糖尿病及肥胖/超重等患者的治疗，目前正在积极 推进III期临床试验。另外，RAY1225注射液获批开展新增适应症治疗"代谢相关脂肪性肝炎"的药物临床 试验。 ...

Group 1 - The core viewpoint of the news is that several listed companies have received target price upgrades from brokers, with notable increases for Guizhou Moutai, Zhongji Xuchuang, and Milkway, reflecting strong market confidence in these companies [1][2]. Group 2 - On January 19, the companies with the highest target price increases were Guizhou Moutai (35.17%), Zhongji Xuchuang (31.96%), and Milkway (29.95%), belonging to the liquor, communication equipment, and logistics industries respectively [1][2]. - A total of 17 listed companies received broker recommendations on January 19, with Zhongsheng Pharmaceutical receiving two recommendations, while Inner Mongolia Huadian and Foreign Service Holdings received one each [2][3]. Group 3 - Three companies received their first coverage from brokers on January 19: Foreign Service Holdings (rated "Buy" by Zhongyin International Securities), Qianli Technology (rated "Buy" by Dongwu Securities), and Zhongsheng Pharmaceutical (rated "Recommended" by Guolian Minsheng Securities) [3][4].

Group 1 - The core viewpoint of the article highlights the target price increases for several listed companies, with Guizhou Moutai, Zhongji Xuchuang, and Milkway leading the rankings with target price increases of 35.17%, 31.96%, and 29.95% respectively, across the liquor, communication equipment, and logistics industries [1][2] Group 2 - On January 19, a total of 17 listed companies received broker recommendations, with Zhongsheng Pharmaceutical receiving recommendations from 2 brokers, while Inner Mongolia Electric Power and Foreign Service Holdings received recommendations from 1 broker each [2][3] Group 3 - Three companies received their first coverage on January 19, including Foreign Service Holdings rated "Buy" by Zhongyin International Securities, Qianli Technology rated "Buy" by Dongwu Securities, and Zhongsheng Pharmaceutical rated "Recommended" by Guolian Minsheng Securities [3][4]

Core Viewpoint - On January 19, several brokerage firms provided target price recommendations for listed companies, with notable increases in target prices for Guizhou Moutai, Zhongji Xuchuang, and Milkewei, indicating strong potential in the liquor, communication equipment, and logistics industries respectively [1]. Group 1: Target Price Increases - Guizhou Moutai received a target price increase of 35.17%, with a highest target price of 1860.00 yuan [2]. - Zhongji Xuchuang's target price increased by 31.96%, with a highest target price of 799.00 yuan [2]. - Milkewei's target price rose by 29.95%, with a highest target price of 79.14 yuan [2]. Group 2: Brokerage Recommendations - A total of 17 listed companies received brokerage recommendations on January 19, with Zhongsheng Pharmaceutical receiving recommendations from 2 firms, while Inner Mongolia Huadian and Foreign Service Holdings received 1 recommendation each [3]. - Zhongsheng Pharmaceutical was the only company with multiple recommendations, indicating strong interest in the traditional Chinese medicine sector [3]. Group 3: First-Time Coverage - Three companies received first-time coverage on January 19, including Foreign Service Holdings with a "Buy" rating from Zhongyin International Securities, Qianli Technology with a "Buy" rating from Dongwu Securities, and Zhongsheng Pharmaceutical with a "Recommended" rating from Guolian Minsheng Securities [4].

Investment Rating - The investment rating for the company is maintained at "Buy-A" with a 12-month target price of 26.68 CNY per share [5]. Core Insights - The company has entered into a licensing agreement with Qilu Pharmaceutical to commercialize the GLP-1/GIP dual-target drug RAY1225 in China, which is expected to lead to significant sales growth [2][3]. - The company retains all rights to RAY1225 outside of China, including clinical development and marketing [2]. - Qilu Pharmaceutical's strong commercialization capabilities position RAY1225 for successful market entry and sales expansion in China [3]. Financial Projections - Projected revenues for the company from 2025 to 2027 are 28.53 billion CNY, 32.81 billion CNY, and 37.41 billion CNY, respectively [3]. - Expected net profits for the same period are 3.02 billion CNY, 3.78 billion CNY, and 4.46 billion CNY [3]. - The company is anticipated to enter a phase of realization of its innovative transformation, justifying a PE valuation of 60 times for 2026 [3]. Market Performance - As of January 16, 2026, the company's stock price was 22.10 CNY, with a total market capitalization of approximately 18.78 billion CNY [5]. - The stock has shown significant performance with a 12-month absolute return of 94.0% [6].